Expert consensus statement on Kangfu Xiaoyan Suppository in treatment of pelvic inflammatory in clinical practice.
10.19540/j.cnki.cjcmm.20190726.501
- Author:
Lian-Xin WANG
1
;
Li-Hui HOU
2
;
Yan-Ming XIE
1
;
Kun MA
3
;
Su-Lun SUN
4
;
Zhe JIN
5
;
Hui-Lan DU
6
;
Dong-Mei WANG
7
;
Hong ZHAO
8
;
Yan-Feng LIU
4
;
Ling TANG
4
;
Kuan-Yong SHU
9
;
Cui-Zhen ZHANG
10
;
Wei SHI
7
;
Si-Yan ZHAN
11
;
Jian-Ping LIU
12
;
Wei CHEN
12
;
Yao-Long CHEN
13
Author Information
1. Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences Beijing 100700,China.
2. the First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine Harbin 150040,China.
3. China Academy of Chinese Medical Sciences Beijing 100700,China.
4. Dongzhimen Hospital of Beijing University of Chinese Medicine Beijing 100700,China.
5. Dongfang Hospital of Beijing University of Chinese Medicine Beijing 100078,China.
6. Hebei Medical University Shijiazhuang 050017,China.
7. Affiliated Hospital of Shandong University of Traditional Chinese Medicine Ji'nan 250014,China.
8. China-Japan Friendship Hospital Beijing 100029,China.
9. Jiangxi Maternal and Child Health Hospital Nanchang 330006,China.
10. Xiyuan Hospital,China Academy of Chinese Medical Sciences Beijing 100091,China.
11. Evidence-based Medicine Center,Beijing University of Chinese Medicine Beijing 100900,China.
12. Evidence-based Medicine Center,Peking University Beijing 100191,China.
13. Evidence-based Medicine Center of Lanzhou University Lanzhou 730000,China.
- Publication Type:Journal Article
- Keywords:
GRADE;
Kangfu Xiaoyan Suppository;
expert consensus;
pelvic inflammatory disease;
recommendation
- MeSH:
Consensus;
Drugs, Chinese Herbal/therapeutic use*;
Female;
Humans;
Medicine, Chinese Traditional;
Nonprescription Drugs;
Pelvic Inflammatory Disease/drug therapy*;
Suppositories
- From:
China Journal of Chinese Materia Medica
2019;44(20):4350-4353
- CountryChina
- Language:Chinese
-
Abstract:
Kangfu Xiaoyan Suppository is widely used in the treatment of gynecological inflammatory diseases. Long-term clinical application and a certain amount of research evidences show that Kangfu Xiaoyan Suppository can alleviate the clinical symptoms of pelvic inflammatory diseases,reduce the recurrence rate,and relieve sequelae,with a better safety and economic characteristics. As a type of nationally protected traditional Chinese medicine and type B medicine included in medical insurance,it has been selected as a Chinese patent medicine for rectal administration. It was included in the Guidelines for diagnosis and treatment of common gynecological diseases of traditional Chinese medicine published by the Chinese Academy of Traditional Chinese Medicine in 2012,the Pelvic inflammatory diseases diagnosis and treatment guidelines issued by the Infectious Diseases Collaborative Group of the Obstetrics and Gynecology Branch of the Chinese Medical Association in 2014,and the group standard of Single use of traditional Chinese medicine/combined antibiot guidelines for clinical practice-pelvic inflammatory diseases of the Chinese Academy of Traditional Chinese Medicine in 2017. To further enhance clinicians' understanding of the drug and better guide its rational clinical use,experts from the field of gynecology of traditional Chinese and Western medicine were invited to develop and compile this expert consensus. This consensus takes full account of clinical evidences and expert clinical experience,and form recommendations for clinical problems based on evidences and consensus recommendations for clinical problems without evidence by nominal grouping method. The expert consensus is mainly formed in the consideration of six factors: quality of evidence,economy,efficacy,adverse reactions,patient acceptability and others. Based on clinical research evidences and expert experience,this consensus provides a preliminary reference for the clinical use of the drug in a concise and clear format. However,evidence-based support is still required in a large number of high-quality studies,and this consensus will be revised in the future according to new clinical problems and the update of evidence-based evidence in practical application.
